Data / Drug companies / Patheon Inc.
Patheon Inc.: 55 products in the FDA NDC directory, labeler code 66406
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Patheon Inc. (labeler code 66406) lists 55 products in the FDA National Drug Code Directory. By type: 55 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on May 15, 2026.
The request: Watch Patheon Inc. (FDA labeler code 66406): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 66406
- Products in commercial distribution
- 55
- Packages
- 66
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 3
- Products with a marketing end date set
- 2
- Earliest marketing start
- December 15, 1952
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Drugs for further processing | 55 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 55 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 16 | 29.1% |
| Tablet | 15 | 27.3% |
| Capsule, gelatin coated | 5 | 9.1% |
| Tablet, extended release | 3 | 5.5% |
| Solution | 3 | 5.5% |
| Tablet, coated | 3 | 5.5% |
| Tablet, film coated, extended release | 3 | 5.5% |
| Capsule | 2 | 3.6% |
| Tablet, multilayer, extended release | 2 | 3.6% |
| Powder | 1 | 1.8% |
| Suspension | 1 | 1.8% |
| Tablet, for suspension | 1 | 1.8% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Tetraferric tricitrate decahydrate | 66406-0280 | Tablet, coated | Drugs for further processing | May 15, 2026 |
| Dextromethorphan hydrobromide and bupropion hydrochloride | 66406-0467 | Tablet, multilayer, extended release | Drugs for further processing | May 1, 2026 |
| Sirolimus solution | 66406-0465 | Solution | Drugs for further processing | March 11, 2026 |
| Acoramidis hydrochloride | 66406-0460 | Tablet, film coated | Drugs for further processing | September 15, 2025 |
| Famotidine | 66406-0446 | Tablet, film coated | Drugs for further processing | March 11, 2024 |
| Emtricitabine and tenofovir disoproxil fumarate | 66406-0464 | Tablet, film coated | Drugs for further processing | January 13, 2023 |
| Emtricitabine and tenofovir disoproxil fumarate | 66406-0463 | Tablet, film coated | Drugs for further processing | January 13, 2023 |
| Emtricitabine and tenofovir disoproxil fumarate | 66406-0462 | Tablet, film coated | Drugs for further processing | January 13, 2023 |
| Voxelotor | 66406-0442 | Tablet, film coated | Drugs for further processing | October 14, 2022 |
| Sodium phenylbutyrate and ursodoxicoltaurine | 66406-0338 | Powder | Drugs for further processing | September 29, 2022 |
| Dextromethorphan hydrobromide and bupropion hydrochloride | 66406-0336 | Tablet, multilayer, extended release | Drugs for further processing | August 18, 2022 |
| Molnupiravir | 66406-0332 | Capsule | Drugs for further processing | December 23, 2021 |
| Voxelotor | 66406-0333 | Tablet, for suspension | Drugs for further processing | December 17, 2021 |
| Oteseconazole | 66406-0334 | Capsule, gelatin coated | Drugs for further processing | November 5, 2021 |
| Lumateperone | 66406-0300 | Capsule | Drugs for further processing | February 1, 2020 |
| Voxelotor | 66406-0301 | Tablet, film coated | Drugs for further processing | November 25, 2019 |
| Bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate | 66406-0273 | Tablet | Drugs for further processing | February 7, 2018 |
| Atazanavir sulfate and cobicistat | 66406-0289 | Tablet | Drugs for further processing | January 29, 2015 |
| Tedizolid phosphate | 66406-0206 | Tablet, coated | Drugs for further processing | June 20, 2014 |
| Eslicarbazepine acetate | 66406-0327 | Tablet | Drugs for further processing | April 7, 2014 |
| Eslicarbazepine acetate | 66406-0222 | Tablet | Drugs for further processing | April 7, 2014 |
| Eslicarbazepine acetate | 66406-0204 | Tablet | Drugs for further processing | April 7, 2014 |
| Eslicarbazepine acetate | 66406-0203 | Tablet | Drugs for further processing | April 7, 2014 |
| Apremilast | 66406-0242 | Tablet, film coated | Drugs for further processing | March 25, 2014 |
| Apremilast | 66406-0241 | Tablet, film coated | Drugs for further processing | March 25, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.